<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352273</url>
  </required_header>
  <id_info>
    <org_study_id>CMEK162X2102</org_study_id>
    <secondary_id>2010-023812-14</secondary_id>
    <nct_id>NCT01352273</nct_id>
  </id_info>
  <brief_title>MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations</brief_title>
  <official_title>A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array Biopharma, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      This is a multi- center, open-label, dose finding, Phase Ib study to be conducted in two&#xD;
      stages: a dose escalation part to determine the maximum tolerated dose (MTD) safety and&#xD;
      tolerability of concurrent administration of MEK162 and RAF265, followed by an expansion part&#xD;
      to further assess the safety and preliminary anti-tumor efficacy of this oral combination&#xD;
      within two separate patient populations: i) patients with advanced solid tumors harboring&#xD;
      BRAFV600E mutations or ii) patients with advanced solid tumors harboring RAS mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities</measure>
    <time_frame>during the first 28 days of treatment with RAF265 and MEK162</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and serious adverse events</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess preliminary anti-tumor activity of the combination</measure>
    <time_frame>every 8 weeks of treatment</time_frame>
    <description>CT scan will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor skin and blood samples will be collected before and during treatment with RAF265 and MEK162 to assess the combination's effects on the RAF/MEK/MAPK pathway with the clinical outcomes</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time versus plasma concentration profiles of RAF265 and MEK162</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>MEK162 + RAF265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162 + RAF265</intervention_name>
    <arm_group_label>MEK162 + RAF265</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with histologically or cytologically confirmed and non-resectable advanced solid&#xD;
        tumors for which no further effective standard therapy exists.&#xD;
&#xD;
          -  The patients' tumors must contain documented activating somatic BRAFV600E* , NRAS or&#xD;
             KRAS mutations (except for pancreatic cancer)&#xD;
&#xD;
          -  All patients enrolled MUST provide fresh or archival tumor samples at baseline to&#xD;
             enable central confirmation of BRAF or KRAS/NRAS mutations&#xD;
&#xD;
          -  Measurable, or non-measurable but evaluable disease as determined by RECIST&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate hepatic and renal function&#xD;
&#xD;
          -  Adequate cardiovascular function&#xD;
&#xD;
          -  Negative serum β HCG test (female patients of childbearing potential only) within 72&#xD;
             hrs prior to first dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of primary central nervous system tumors or brain metastases&#xD;
             or who have signs/symptoms attributable to brain metastases and have not been assessed&#xD;
             with radiologic imaging to rule out the presence of brain metastases&#xD;
&#xD;
          -  Current evidence of retinal disease; or ophthalmopathy as assessed by ophthalmologic&#xD;
             examination at baseline that would be considered a risk factor for CSR/RVO (e.g.,&#xD;
             optic disc cupping, visual field defects, IOP &gt; 21 mm Hg)&#xD;
&#xD;
          -  Impaired cardio-/vascular function or clinically significant cardiovascular diseases,&#xD;
             including any of the following:&#xD;
&#xD;
               -  History/evidence of acute coronary syndromes (including MI, unstable angina,&#xD;
                  CABG, coronary angioplasty, or stenting) ≤ 6 months prior to starting study drugs&#xD;
&#xD;
               -  Thromboembolic event (DVT, CVA, PE) ≤ 6 months prior to starting study&#xD;
&#xD;
               -  Symptomatic CHF, history or current evidence of clinically significant cardiac&#xD;
                  arrhythmia and/or conduction abnormality&#xD;
&#xD;
               -  Uncontrolled arterial hypertension, defined as BP &gt; 140/100 mmHg (average of 3&#xD;
                  consecutive readings)&#xD;
&#xD;
          -  History of melena, hematemesis or hemoptysis within the last 3 months&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test (&gt; 5 mIU/mL)&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute Moffitt 4</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University OHSU 3</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah / Huntsman Cancer Institute Huntman 2</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced Solid tumors</keyword>
  <keyword>harboring RAS</keyword>
  <keyword>harboring BRAFV600E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

